ACURA PHARM : The Shuman Law Firm Announces the Filing of a Class Action Lawsuit against Acura Pharmaceuticals, Inc.
10/21/2010| 02:10pm US/Eastern
Recommend:
The Shuman Law Firm (www.shumanlawfirm.com)
today announced that a class action lawsuit has been filed in the United
States District Court for the Northern District of Illinois on behalf of
purchasers of the common stock of Acura Pharmaceuticals, Inc. ("Acura"
or the "Company") (Nasdaq: ACUR) between February 21, 2006 and April 22,
2010, inclusive (the "Class Period").
If you wish to discuss this action or have any questions concerning this
notice or your rights and interests with respect to this matter, please
contact Rusty E. Glenn toll-free at 866-974-8626 or email Mr. Glenn at rusty@shumanlawfirm.com.
The complaint charges certain current and/or former Acura executive
officers and directors of violations of the Securities Exchange Act of
1934. The complaint alleges that during the Class Period, defendants
concealed material adverse facts about the Company's lead product
candidate, Acurox, including: (i) its clinical data was defective and
its clinical studies were not properly designed; (ii) Acura had wholly
ignored specific directives from the U.S. Food and Drug Administration
(the "FDA") over the past four years as to specific clinical trials and
evidence Acura had to demonstrate; and (iii) no evidence had been
presented to the FDA that the niacin addictive discouraged abusers from
abusing oxycodone.
On April 20, 2010, the FDA announced that the Company's clinical data
and studies were substandard. Upon this news, Acura's stock price
declined 42.5% in one day, to close at $6.25 in afterhours trading.
Further, on April 22, 2010, the FDA Joint Panel voted nineteen to one
against approving Acurox. As a result of these disclosures, the
Company's stock price declined an additional 39%, to $3.20 per share, in
the pre-market trading on April 23, 2010.
If you purchased Acura common stock during the Class Period, you may
request that the Court appoint you as lead plaintiff of the class no
later than November 9, 2010. A lead plaintiff is a class member that
acts on behalf of other class members in directing the litigation.
Although your ability to share in any recovery is not affected by the
decision whether or not to seek appointment as a lead plaintiff, lead
plaintiffs make important decisions which could affect the overall
recovery for class members.
The Shuman Law Firm represents investors throughout the nation,
concentrating its practice in securities class actions and shareholder
derivative actions.
The Shuman Law Firm
Rusty E. Glenn, Esq., 866-974-8626
Fax:
303-484-4886
rusty@shumanlawfirm.com
www.shumanlawfirm.com
© Business Wire 2010
Recommend :
